Search research articles
Contact Us
Filters
Showing results (91-100 of 109) with videos related to
Page
of 11
Sort By:
The New England Journal of Medicine
|
March 15, 2001
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
D J Slamon, B Leyland-Jones, S Shak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1996
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group
A Buzdar, W Jonat, A Howell, et al.
Cancer
|
September 18, 1998
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group
A U Buzdar, W Jonat, A Howell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 2002
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
W Eiermann, S Paepke, J Appfelstaedt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 15, 2008
Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study
J Rom, G von Minckwitz, W Eiermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2001
Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study
G von Minckwitz, S D Costa, G Raab, et al.
Zentralblatt Fur Gynakologie
|
July 23, 2005
[Systemic therapy of operable carcinoma of the breast]
M Kaufmann, W Jonat, W Eiermann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 9, 2012
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
W Eiermann, M Rezai, S Kümmel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study
J Furlanetto, W Eiermann, F Marmé, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 24, 2012
Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer
M Schmidt, D Rüttinger, M Sebastian, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 109) with videos related to
Sort By:
Page
of 11
The New England Journal of Medicine
|
March 15, 2001
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
D J Slamon, B Leyland-Jones, S Shak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1996
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group
A Buzdar, W Jonat, A Howell, et al.
Cancer
|
September 18, 1998
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group
A U Buzdar, W Jonat, A Howell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 2002
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
W Eiermann, S Paepke, J Appfelstaedt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 15, 2008
Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study
J Rom, G von Minckwitz, W Eiermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2001
Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study
G von Minckwitz, S D Costa, G Raab, et al.
Zentralblatt Fur Gynakologie
|
July 23, 2005
[Systemic therapy of operable carcinoma of the breast]
M Kaufmann, W Jonat, W Eiermann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 9, 2012
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
W Eiermann, M Rezai, S Kümmel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study
J Furlanetto, W Eiermann, F Marmé, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 24, 2012
Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer
M Schmidt, D Rüttinger, M Sebastian, et al.
Page
of 11